Page 1 of 1

2023-Tang et al-J Immunother Cancer

PostPosted: Tue Feb 28, 2023 4:36 pm
by mleipold
"Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability"
Jianghui Tang, Jianpeng Sheng, Qi Zhang, Yongtao Ji, Xun Wang, Junlei Zhang, Jiangchao Wu, Jinyuan Song, Xueli Bai, Tingbo Liang
J Immunother Cancer. 2023, 11, e006119

- no dataset accession given